TY - JOUR
T1 - Cell-mediated drug delivery
AU - Batrakova, Elena V.
AU - Gendelman, Howard E.
AU - Kabanov, Alexander V.
N1 - Funding Information:
This work was supported by the United States National Institutes of Health grants 1RO1 NS057748 (to EV Batra-kova), 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR 15635, P01 MH64570, 5 P01 DA026146, 1P01 DA028555, P01 NS43985 (to HE Gendelman), RO1 NS051334, 2RO1 CA89225, 1 R01 CA116591, UO1 CA151806, 1P20 RR021937, the United States Department of Defense grants W81XWH-09-1-0386 and DoD USAMRMC 06108004, and the Government of Russian Federation grants 02.740.11.523 and 11.G4.31.0004 (to AV Kabanov).
PY - 2011/4
Y1 - 2011/4
N2 - Introduction: Drug targeting to sites of tissue injury, tumor or infection with limited toxicity is the goal for successful pharmaceutics. Immunocytes (including mononuclear phagocytes (dendritic cells, monocytes and macrophages), neutrophils and lymphocytes) are highly mobile; they can migrate across impermeable barriers and release their drug cargo at sites of infection or tissue injury. Thus, immune cells can be exploited as Trojan horses for drug delivery. Areas covered: This paper reviews how immunocytes laden with drugs can cross the blood-brain or blood-tumor barriers to facilitate treatments for infectious diseases, injury, cancer, or inflammatory diseases. The promises and perils of cell-mediated drug delivery are reviewed, with examples of how immunocytes can be harnessed to improve therapeutic end points. Expert opinion: Using cells as delivery vehicles enables targeted drug transport and prolonged circulation times, along with reductions in cell and tissue toxicities. Such systems for drug carriage and targeted release represent a new disease-combating strategy being applied to a spectrum of human disorders. The design of nanocarriers for cell-mediated drug delivery may differ from those used for conventional drug delivery systems; nevertheless, engaging different defense mechanisms in drug delivery may open new perspectives for the active delivery of drugs.
AB - Introduction: Drug targeting to sites of tissue injury, tumor or infection with limited toxicity is the goal for successful pharmaceutics. Immunocytes (including mononuclear phagocytes (dendritic cells, monocytes and macrophages), neutrophils and lymphocytes) are highly mobile; they can migrate across impermeable barriers and release their drug cargo at sites of infection or tissue injury. Thus, immune cells can be exploited as Trojan horses for drug delivery. Areas covered: This paper reviews how immunocytes laden with drugs can cross the blood-brain or blood-tumor barriers to facilitate treatments for infectious diseases, injury, cancer, or inflammatory diseases. The promises and perils of cell-mediated drug delivery are reviewed, with examples of how immunocytes can be harnessed to improve therapeutic end points. Expert opinion: Using cells as delivery vehicles enables targeted drug transport and prolonged circulation times, along with reductions in cell and tissue toxicities. Such systems for drug carriage and targeted release represent a new disease-combating strategy being applied to a spectrum of human disorders. The design of nanocarriers for cell-mediated drug delivery may differ from those used for conventional drug delivery systems; nevertheless, engaging different defense mechanisms in drug delivery may open new perspectives for the active delivery of drugs.
KW - Cell carriers
KW - drug delivery
KW - immunocytes
KW - nanoparticles
KW - targeted drug transport
UR - http://www.scopus.com/inward/record.url?scp=79952916450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952916450&partnerID=8YFLogxK
U2 - 10.1517/17425247.2011.559457
DO - 10.1517/17425247.2011.559457
M3 - Review article
C2 - 21348773
AN - SCOPUS:79952916450
SN - 1742-5247
VL - 8
SP - 415
EP - 433
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 4
ER -